4 research outputs found
Biologicals in childhood severe asthma : the European PERMEABLE survey on the status quo
Introduction Severe asthma is a rare disease in children, for which three biologicals, anti-immunoglobulin E, anti-interleukin-5 and anti-IL4RA antibodies, are available in European countries. While global guidelines exist on who should receive biologicals, knowledge is lacking on how those guidelines are implemented in real life and which unmet needs exist in the field. In this survey, we aimed to investigate the status quo and identify open questions in biological therapy of childhood asthma across Europe. Methods Structured interviews regarding experience with biologicals, regulations on access to the different treatment options, drug selection, therapy success and discontinuation of therapy were performed. Content analysis was used to analyse data. Results We interviewed 37 experts from 25 European countries and Turkey and found a considerable range in the number of children treated with biologicals per centre. All participating countries provide public access to at least one biological. Most countries allow different medical disciplines to prescribe biologicals to children with asthma, and only a few restrict therapy to specialised centres. We observed significant variation in the time point at which treatment success is assessed, in therapy duration and in the success rate of discontinuation. Most participating centres intend to apply a personalised medicine approach in the future to match patients a priori to available biologicals. Conclusion Substantial differences exist in the management of childhood severe asthma across Europe, and the need for further studies on biomarkers supporting selection of biologicals, on criteria to assess therapy response and on how/when to end therapy in stable patients is evident.Peer reviewe
Association of PPAR polymorphisms with cytokine levels in allergic rhinitis
Our aim was to study the association of Pro12Ala and exon6 C161T polymorphisms of PPARgamma and intron7 G/C polymorphisms of PPAR-alpha with clinical symptoms, peak nasal inspiratory flow values, serum soluble TNF-alpha, TNF-R1, Fas, Fas ligand and IgE concentrations in patients with seasonal allergic rhinitis during and after pollen season. We performed a follow-up study of 66 Hungarian patients with seasonal allergic rhinitis and 180 healthy referent subjects. We used PCR-RFLP technique and ELISA. The distribution of mutant alleles of PPAR-gamma and -alpha did not differ in patients and referent subjects. Patients carrying the mutant 12Ala, exon6 161T alleles of PPAR-gamma and intron7 C allele of PPAR-alpha had significantly higher clinical symptom score values, TNF-alpha and IgE levels and lower peak nasal inspiratory flow values during and after pollen season. The results indicated that nuclear receptors PPAR-gamma and PPAR-alpha are involved in the regulation of inflammatory mediator production in patients with seasonal allergic rhinitis and polymorphisms of the receptors are very likely to contribute to the heterogeneity of clinical and immunological parameters of allergic patients. © 2011 Springer-Verlag
Biologicals in childhood severe asthma : the European PERMEABLE survey on the status quo
Biologicals in childhood severe asthma: the European PERMEABLE survey on the status quo
Introduction Severe asthma is a rare disease in children, for which
three biologicals, anti-immunoglobulin E, anti-interleukin-5 and
anti-IL4RA antibodies, are available in European countries. While global
guidelines exist on who should receive biologicals, knowledge is lacking
on how those guidelines are implemented in real life and which unmet
needs exist in the field. In this survey, we aimed to investigate the
status quo and identify open questions in biological therapy of
childhood asthma across Europe.
Methods Structured interviews regarding experience with biologicals,
regulations on access to the different treatment options, drug
selection, therapy success and discontinuation of therapy were
performed. Content analysis was used to analyse data.
Results We interviewed 37 experts from 25 European countries and Turkey
and found a considerable range in the number of children treated with
biologicals per centre. All participating countries provide public
access to at least one biological. Most countries allow different
medical disciplines to prescribe biologicals to children with asthma,
and only a few restrict therapy to specialised centres. We observed
significant variation in the time point at which treatment success is
assessed, in therapy duration and in the success rate of
discontinuation. Most participating centres intend to apply a
personalised medicine approach in the future to match patients a priori
to available biologicals.
Conclusion Substantial differences exist in the management of childhood
severe asthma across Europe, and the need for further studies on
biomarkers supporting selection of biologicals, on criteria to assess
therapy response and on how/when to end therapy in stable patients is
evident